Savikalpa Sciences
 | |
| Industry | Health and Wellness |
|---|---|
| Founded | 2020 |
| Headquarters | New Delhi, India |
Key people | Raghav Priyadarshi (Co-founder & CEO) |
| Website | savikalpa |
Savikalpa Sciences is an India-based health and wellness firm that specializes in providing high-quality cannabinoid and phytomedicine products designed to treat various medical conditions.[1][2]
History
The company was founded in 2020 by a team of cannabis, CPG, and policy sector experts from India, Switzerland, and Canada, and is headquartered in New Delhi. Since its inception, Savikalpa Sciences has become a leading supplier of research-backed cannabinoid treatment products.[3]
Savikalpa Sciences wants to make India the hub of global cannabinoid medicine, drawing inspiration from India's traditional use of cannabis as a therapeutic herb, which Ayurveda has acknowledged and documented. The company offers a range of cannabinoid products specifically curated to relieve joint pain, migraine, headaches, menstrual cramps, chronic pain, neuropathic pain, insomnia, inflammatory disorders, stress, and anxiety.[4][5]
The company has partnered with leading clinical research organizations and academic institutions to deepen cannabinoid research and build a portfolio of safe and effective branded cannabinoid formulations for India and global markets.[6]
In addition to offering high-quality cannabinoid products, Savikalpa Sciences provides a virtual clinic platform dedicated to cannabinoid treatment. Through its virtual clinic, Savikalpa Sciences offers video consultations with experienced physicians, assuring a high standard of care and guided treatment for patients who might benefit from oral cannabinoid medicine.[7]
Savikalpa Sciences is committed to advancing cannabis science and medicine and has established a dedicated "Academy" information hub that collates the latest research and learnings from global clinical practice, providing a one-stop-shop for all queries about cannabis science and medicine.[8]
Savikalpa Sciences is actively engaging with all stakeholders including doctors, patients, clinicians, academia, and state and central government departments to raise awareness of the potential opportunity of cannabinoid medicines, which could contribute to decreasing India’s health burden, and position India as a global leader in phytopharmaceutical medicine. The company is working to ensure that appropriate regulatory approaches are adopted to support this emerging industry.[9]
Products
- Shunyata - Balance
- Shunyata - Calm
- Shunyata - Pain
- Shunyata - Relief
- Shunyata - Cramp Relief
- Shunyata - Migraine Relief
- SVAHA
References
- ↑ "Shift Focus To Yourself: A Guide To Cannabis Wellness with Savikalpa Sciences | LBB". LBB, Mumbai. Retrieved 12 May 2023.
- ↑ "Ela Capital Takes A Position in Gather, Ahead of Series A Funding". Yahoo Finance. Retrieved 12 May 2023.
- ↑ "Savikalpa Sciences Company Insights, Tech Stack, and Competitors | 6sense". 6sense.com. Retrieved 12 May 2023.
- ↑ White, Beverly (16 January 2023). "Hemp brand Wildleaf bets on medical cannabis space". YourStory.com. Retrieved 12 May 2023.
- ↑ "Does India Have Patience, Will And Resources To Build World's Top Cannabis Medicine Industry?". IndiaTimes. 26 March 2022. Retrieved 12 May 2023.
- ↑ "Savikalpa Sciences | Buy CBD Oil, Hemp Oil, …". Flipboard. Retrieved 12 May 2023.
- ↑ "We are trying to make cannabinoid formulations more affordable: Raghav Priyadarshi, Savikalpa Sciences - ET HealthWorld". ETHealthworld.com. Retrieved 12 May 2023.
- ↑ "Chronic pain is an ailment that nobody needs to suffer". mint. 2 May 2022. Retrieved 12 May 2023.
- ↑ "Don't Run Into Glass: Cannabis: Back with a Bhang on Apple Podcasts". Apple Podcasts. Retrieved 12 May 2023.